Table IV.
Study outcomes of aPCs/BMPCs, viability and % PCs/% all nucleated cells per patient, location and order of aspirate pull.
| Location | 1 | 2 | 3 | 4 | p-Value | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viability | Right | First-pull EDTA | 92% | 82% | 78% | 89% | 82% | 71% | 74% | 80% | 80% | 61% | 81% | 0.0039 |
| Second-pull heparin | 91% | 96% | 88% | 92% | 92% | 92% | 94% | 95% | 92% | 91% | 92% | |||
| Left | First-pull EDTA | 94% | 70% | 71% | 89% | 84% | 76% | 62% | 83% | 82% | 73% | 79% | 0.0020 | |
| Second-pull heparin | 95% | 94% | 84% | 94% | 89% | 93% | 96% | 96% | 94% | 97% | 94% | |||
| 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | |||||
|
|
||||||||||||||
| Unilateral | First-pull heparin | 80% | 99% | 93% | 95% | 88% | 97% | 97% | 98% | 87% | 91% | 94% | 1.00 | |
| Second-pull EDTA | 96% | 96% | 93% | 95% | 90% | 87% | 95% | 92% | 91% | 94% | 94% | |||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |||||
|
|
||||||||||||||
| % PCs/% all nucleated cells | Right | First-pull EDTA | 0.60% | 0.04% | 0.04% | 27.00% | 8.00% | 6.00% | 0.60% | 1.80% | 2.30% | 1.10% | 1.45% | 0.0078 |
| Second-pull heparin | 0.50% | 0.12% | 0.04% | 25.00% | 6.00% | 3.00% | 0.10% | 0.80% | 1.90% | 0.52% | 0.66% | |||
| Left | First-pull EDTA | 0.06% | 0.60% | 0.16% | 19.00% | 5.30% | 5.30% | 1.10% | 2.00% | 0.60% | 0.30% | 0.85% | 0.049 | |
| Second-pull heparin | 0.02% | 0.24% | 0.02% | 17.00% | 5.40% | 2.00% | 0.06% | 0.50% | 0.90% | 0.23% | 0.37% | |||
| 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | |||||
|
|
||||||||||||||
| Unilateral | First-pull heparin | 3.95% | 0.12% | 0.49% | 41.00% | 0.67% | 0.95% | 0.15% | 6.90% | 0.80% | 0.52% | 0.74% | 0.045 | |
| Second-pull EDTA | 0.41% | 0.52% | 0.19% | 8.40% | 0.42% | 0.83% | 0.26% | 2.70% | 0.50% | 0.25% | 0.46% | |||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |||||
|
|
||||||||||||||
| aPCs/BMPCs | Right | First-pull EDTA | 97% | 42% | 92% | >99% | 97% | >99% | >99% | 94% | 97% | 96% | 97% | 0.38 |
| Second-pull heparin | 97% | 42% | 88% | >99% | 97% | >99% | >99% | 90% | 96% | 98% | 97% | |||
| Left | First-pull EDTA | 93% | 42% | 91% | >99% | 97% | >99% | >99% | 96% | 98% | 98% | 97.5% | 1.00 | |
| Second-pull heparin | 97% | 42% | 90% | >99% | 98% | >99% | >99% | 82% | 97% | 99% | 97.5% | |||
| 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | |||||
|
|
||||||||||||||
| Unilateral | First-pull heparin | >99% | >99% | 97% | >99% | 93% | 97% | 97% | >99% | 99% | 97% | 98% | 1.00 | |
| Second-pull EDTA | >99% | >99% | 96% | >99% | 95% | 97% | 98% | 98% | 98% | 96% | 98% | |||
aPCs/BMPCs, percentage of abnormal plasma cells in the bone marrow plasma cell compartment; PCs, plasma cells; EDTA, ethylene diamine tetraacetic acid.